Chinese/US biotech Terns Pharmaceuticals, Inc. unveiled an $87m series C financing on 5 January, bringing it substantial capital to advance its three-candidate pipeline for non-alcoholic steatohepatitis, with an eye on both monotherapy and possible combinations that address multiple manifestations of the disease such as hepatic fat, fibrosis and inflammation. Based in both Foster City, CA, and Shanghai, Terns is focused primarily on NASH and other liver indications, but also has a nascent cancer program.
New investor Deerfield Management led the round, with partner Elise Wang joining Terns’ board of directors, with additional backing from...






